Small Cap Feast

Small Cap Feast – 17 December 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp):

Total number of AIM Companies trading: *
* As at

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): *

Total number of NEX Growth Market Companies trading: *
* As at

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at

Dish of the Day:

SulNOx Group (SNOX.PL)  – NEX. The Group has developed a methodology and process capable of emulsifying hydrocarbon fuels such as diesel and heavy fuel oil . By January 2014, following preliminary laboratory testing, SulNOx was in a position to suggest that its products resulted in up to a 50% reduction of Nitrogen Oxide (NOx) and a 90% reduction in particulate matter. mkt cap £42.3m.


Off the Menu:

No Leavers Today


Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

NEX Exchange

Green Care Capital  – Investment Vehicle –Hemp, CBD and Medicinal Cannabis . Due 30 Dec. No capital raise.


Breakfast Buffet

Sareum Holdings* (SAR.L) 0.36p £11.1m

AGM Statement-

“2018-19 has been a year of mixed fortunes for the UK life sciences sector and Sareum has not been immune from its effects. Saying that, we have been successful in raising additional funds during the year against a generally difficult climate for financing listed companies in the sector.

These funds are being deployed to advance our proprietary TYK2/JAK1 projects through preclinical development and the Board is pleased to report significant progress has been made with these projects during the year. We also remain cautiously optimistic about the future development of our out-licensed Chk1 project SRA737 with Sierra Oncology, Inc (“Sierra”). This view is based on the encouraging preliminary clinical and preclinical results reported during the year, while recognising that Sierra has reprioritised its resources on the Phase 3 development of momelotinib and is seeking strategic solutions that will enable the further development of SRA737. “The Company continues to engage with potential partners with a view to securing commercial licences for all its products and programmes and we will, of course, keep shareholders updated in this regard as appropriate. “


Tekcapital (TEK.L) 5.25p £3.4m

 The UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that its wholly owned portfolio company Lucyd Ltd, the smartglass developer and operator of a global eShop for tech-enhanced eyewear, has filed five new patents and a trademark1 on its forthcoming line of Bluetooth® audio glasses.

The five patent filings cover the upcoming “Lucyd Loox” line of glasses, which will offer high-utility Bluetooth® features consistent with Lucyd eyewear, with a fashion-focused enhancement such as the ability for the wearer to rapidly and easily disconnect the front plate (the front of the eyeglass frame) from the electronic arms, to switch it with a different plate to change the style and/or lens functionality of the glasses with dramatically enhanced affordability.

Lucyd plans to produce new front plate shapes and patterns over time to accommodate a large range of personal styles, which will be significantly more cost effective than a full new pair of Bluetooth® glasses. For prescription wearers, new plates will also be available at a lower price than a full new frame, allowing customers to quickly switch between blue light blocking lenses, sunglass and other lenses according to their need.


Alien Metals (UFO.L) 0.19p £2.6m

Alien Confirms Confidence In Silver Resource At Elizabeth Hill Silver Project”.  Completion of the acquisition remains conditional on, amongst other matters, satisfactory mutual due diligence on the Project and Alien by the parties, required regulatory approvals and approval by KMG’s shareholders for the distribution .

Elizabeth Hill’s initial 1999 JORC Compliant Resource of 4.05 million ounce (“Moz”) silver at greater than 200 g/t silver: 46,800 tonnes grading 2,700 g/t silver (1.15 oz/t gold equivalent)(Ian Cowden, Iana Pty Ltd, Resource Estimate, Elizabeth Hill Silver Mine, November 1999). 1,170,000 ounces of silver mined between 1998 and 2000 at an average grade of 2,195 g/t silver (70.24 oz/t silver).

Unique mineralisation system which has produced Australia’s largest silver nugget weighing 180 kg (see Figure 1) and many other very large specimens of native silver

Silver resource also present in near surface material via standard open pit mining method above the existing underground workings

Independent reports suggest potential for further high grade material within the existing mine

Depth extension of high grade mineralisation below 100 metres (“m”) untested


Applied Graphene (AGM .L) 16.5p £8.2m

AGM Statement

We continue to work closely with the companies in our sales pipeline in order to secure new product launches.  We are pleased that James Briggs, Halfords, Alltimes and Blocksil have all launched new products containing our materials during the first four months of the current financial year and we look forward to seeing these products develop in the future.


The re-alignment process which commenced in October 2019 is now complete and the anticipated cost reductions have been achieved.  This was a very difficult period for all staff and we appreciate their support and understanding throughout the process.

We presented at IP Group’s Deep Tech Conference in Beijing, China during October 2019 and, as a result, the Group is actively pursuing an increased number of exciting opportunities in Asia.

Our intent remains to become a global graphene market leader and the Board believes that Applied Graphene Materials remains well placed to meet its ambitions.


Ariana Resources (AAU.L) 2.2p £23.3m

Recent resource drilling results obtained from the Kiziltepe Mine.

  • Recent exploration drilling to test for deeper extensions of Arzu South included 16m @ 3.04 g/t Au + 67 g/t Ag and 3m @ 6.25 g/t Au + 129 g/t Ag.

  • Top historical intercepts from three zones of drilling beyond the Arzu South open-pit include 20m @ 3.16 g/t Au + 31 g/t Ag, 8m @ 3.95 g/t Au + 79 g/t Ag and 9m @ 2.37 g/t Au + 126 g/t Ag.

  • Potential for secondary structures associated with Arzu South, in the hangingwall and footwall are highly probable: Arzu South Parallel is a specific example.

  • Revised resource estimates for Kiziltepe are due to be completed during Q1 2020.


Keywords Studios (KWS.L) 1408p £917m

Three acquisitions, in line with the Group’s strategy to be the ‘go to’ technical and creative services platform for the global video games industry.


  • Acquisition of Kantan adds cutting edge Machine Translation technology to the Group that will enable Keywords to provide a world leading machine learning localisation service
  • Acquisition of Ichi expands marketing services with branding expertise that is key to determining the success of a game
  • Acquisition of Syllabes adds a games and film/TV audio recording studio, completing the full suite of services provided out of Keywords’ Montreal services hub
  • The total consideration payable for the three business is 7m, £3.2m and CAD$475k respectively, or c.11.2m for combined last reported revenue of c.4.8m.


President Energy (PPC.L) 2.95p £33.5m

The upstream oil and gas company with a diverse portfolio of production and exploration assets focused primarily in Argentina, comments on recent share price activity.

President notes the recent decline in its share price being a nearly 35% reduction since 1  November 2019 alone , being the date of the last trading update issued by the Company.

There are no materially adverse changes in President’s trading, business or prospects since that time whether micro or macro. In fact there have been improvements in all key performance indicators. Since that time, inter alia, the receivable oil price has made positive progress and President has increased its production by acquisition of the Angostura asset.


Destiny Pharma (DEST.L) 41p £18m

The “clinical stage biotechnology company focused on the development of novel antimicrobial drugs that target clear commercial opportunities and also address the global problem of antimicrobial resistance (AMR), notes that new guidelines from the Asia Pacific Society for Infection Control (APSIC) for the prevention of surgical site infections have been published in the peer-reviewed journal, Antimicrobial Resistance and Infection Control. These guidelines underline the market potential of Destiny Pharma’s lead product XF-73 which is in Phase 2b clinical trials testing its ability to kill Staphylococcus aureus bacteria in the patient’s nose prior to surgery thereby reducing the potential for serious post-surgical bacterial infections including MRSA.”


Block Energy (BLOE.L) 4.8p £18.9m

 The exploration and production company focused on the Republic of Georgia is pleased to announce that well WR-38Z at the Company’s flagship West Rustavi field is flowing naturally following clean-up operations and is ready for production testing. The Company has also prepared nearby well WR-51 for the Field’s next horizontal sidetrack. Following a short period of swabbing, WR-38Z is flowing naturally. The Company has installed and commissioned new production test equipment sourced from North America and will now commence a multi-rate production test extending over several weeks.


Greatland Gold (GGP.L) 1.75p £63m

The precious and base metals exploration and development company, is pleased to announce that further results from diamond drilling at the Company’s 100% owned Firetower project in Tasmania, Australia confirm the presence of additional broad widths of shallow gold mineralisation. In addition, zinc and silver mineralisation has been intersected in the first drill hole at Firetower East.

o  13.5m at 2.00g/t Au from 14.5m (2019FTD008)

o  13.5m at 2.44g/t Au from 59.5m (2019FTD011)

o  38m at 1.12g/t Au from 11m (2019FTD013)


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.